<DOC>
	<DOC>NCT02202551</DOC>
	<brief_summary>This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).</brief_summary>
	<brief_title>Open-Label Safety Study of ADS-5102 in PD Patients With LID</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Signed a current IRB/REB/IECapproved informed consent form Completed all study visits in previous Adamas efficacy study or were ineligible for participation in previous Adamas studies due to having undergone prior deep brain stimulation. Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria On a stable regimen of antiparkinson's medications at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily. History of peak dose dyskinesia that might benefit from specific dyskinesia treatment in the judgment of the subject and clinical investigator Discontinued ADS5102 in previous Adamas efficacy study due to intolerable or unacceptable AEs considered to be related to ADS5102 History of neurosurgical intervention related to Parkinson's disease, with the exception of deep brain stimulation History of seizures since completion of participation in previous Adamas studies or within 2 years History of stroke or TIA since completion of participation in previous Adamas studies or within 2 years History of cancer since completion of participation in previous Adamas studies or within 2 years, with the following exceptions: adequately treated nonmelanomatous skin cancers, localized bladder cancer, nonmetastatic prostate cancer or in situ cervical cancer Presence of cognitive impairment, as evidenced by a MiniMental Status Examination (MMSE) score of less than 24 during screening If female is pregnant or lactating If a sexually active female, is not surgically sterile or at least 2 years postmenopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment. Treatment with an investigational drug (other than ADS5102) or device within 30 days prior to screening Treatment with an investigational biologic within 6 months prior to screening Current or planned participation in another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Levodopa Induced Dyskinesia</keyword>
	<keyword>LID</keyword>
	<keyword>Parkinsonism</keyword>
	<keyword>Parkinson's Disease</keyword>
</DOC>